Literature DB >> 3058569

Growth hormone and carbohydrate intolerance in cirrhosis.

T P Shankar1, S S Solomon, W C Duckworth, T Jerkins, R S Iyer, M A Bobal.   

Abstract

Patients with cirrhosis of the liver often have insulin resistance and elevated circulating growth hormone levels. This study was undertaken (a) to evaluate glucose intolerance, insulin resistance and abnormal growth hormone secretion and (b) to determine if GH suppression improves insulin resistance. Glucose tolerance tests (GTT), intravenous insulin tolerance tests (IVITT), arginine stimulation tests (AST) and glucose clamp studies before and during GH suppression with somatostatin were performed in a group of patients with alcohol-induced liver cirrhosis. During GTT cirrhotic subjects had a 2-hour plasma glucose of 200 +/- 9.8 ng/dl (N = 14) compared to 128 +/- 8.0 ng/dl in normal controls (N = 15), P less than 0.001. Basal GH was elevated in cirrhotic patients and in response to arginine stimulation reached a peak of 17.0 +/- 5.4 ng/ml (N = 7), compared to a peak of 11.3 +/- 1.8 ng/ml in 5 normal controls (P = NS). During IVITT patients with cirrhosis had a glucose nadir of 60.0 +/- 4.0 mg/dl (N = 9), compared to 29.0 +/- 7.0 mg/dl in controls (N = 5), P less than 0.001. Peak GH levels during IVITT were not significantly different in cirrhotics and controls. Glucose utilization rates in 4 patients with cirrhosis of the liver before somatostatin mediated GH suppression was 3.1 +/- 0.5 mg/kg/min and 6.5 +/- 1.5 mg/kg/min during somatostatin infusion, P less than 0.025. We conclude that patients with alcohol induced cirrhosis have sustained GH elevations resulting in insulin resistance which improves after GH suppression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3058569     DOI: 10.1055/s-2007-1010889

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  3 in total

1.  Relation of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels to growth retardation in extrahepatic portal vein obstruction.

Authors:  Lalit Nihal; Mukta R Bapat; Pravin Rathi; Nalini S Shah; Anjana Karvat; Philip Abraham; Shobna J Bhatia
Journal:  Hepatol Int       Date:  2008-09-20       Impact factor: 6.047

2.  Nonalcoholic Fatty liver disease and metabolic syndrome in hypopituitary patients.

Authors:  Ebenezer A Nyenwe; Sarah Williamson-Baddorf; Bradford Waters; Jim Y Wan; Solomon S Solomon
Journal:  Am J Med Sci       Date:  2009-09       Impact factor: 2.378

3.  Prevalence and pattern of growth abnormalities in children with extrahepatic portal vein obstruction: Response to shunt surgery.

Authors:  Toufeeq Ahmad Mir; Raiz Ahmad Misgar; Bashir Ahmad Laway; Omar Javed Shah; Zafar Amin Shah; Showkat Ali Zargar
Journal:  Indian J Endocrinol Metab       Date:  2016 Nov-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.